Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DepoCyte for CNS relapse prophylaxis in aggressive non-Hodgkin lymphoma
2006-001888-40Phase 2Terminated
- Sponsor
- Mundipharma Research
- Start
- Jul 2006
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liposomal cytarabine in non-Hodgkin lymphoma (NHL), Carcinomatous Meningitis (CM) and central nervous system lymphoma, sponsored by Mundipharma Research. Primary endpoints: Incidence of leptomeningeal CNS relapse and Overall safety profile. Started Jul 2006; status: terminated.
02
Drugs
liposomal cytarabine
03
Conditions
non-Hodgkin lymphoma (NHL)Carcinomatous Meningitis (CM)central nervous system lymphoma
Beyond the preview
Go deeper on 2006-001888-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001888-40.